INGREZZA

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) shares fell sharply Wednesday following a disappointing phase 2 study of Ingrezza (valbenazine), a pediatric Tourette's syndrome drug. The company announced after Tuesday's close that Ingrezza didn't show a statistically significant difference on...

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) investors got a pleasant surprise when the FDA approved the company’s Ingrezza drug for treatment of tardive dyskinesia (TD). While the approval itself was expected, Baird analyst Brian Skorney says the FDA’s generous labeling puts the drug at...

BMO Capital Markets picked Neurocrine Biosciences, Inc.. (NASDAQ: NBIX) to Outperform expectations on Wednesday, one day after the the U.S. Food and Drug Administration approved the pharmaceutical company’s drug for the treatment of tardive dyskinesia, a neurological disorder. It was the...

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is on the verge of becoming a commercial biotech company, as its PDUFA date for Ingrezza in tardive dyskynesia (TD) approaches. The FDA is expected to announce a decision in early April. Consequently, Neurocrine’s management team has shifted its...

Biotech stocks are regaining some lost momentum after Wednesday's Trump-inspired selloff that took a toll on the sentiment on pharma sector. The weakness was so stark that it made CNBC's Brian Sullivan tweet that biotechs/healthcare was the only sector to have been left out of what seemed...